Exchange Traded Concepts LLC decreased its position in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 12.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,931 shares of the company’s stock after selling 14,089 shares during the period. Exchange Traded Concepts LLC owned approximately 0.07% of Compass Therapeutics worth $180,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. Opaleye Management Inc. bought a new stake in Compass Therapeutics during the 1st quarter worth approximately $6,277,000. CM Management LLC raised its holdings in shares of Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock worth $614,000 after acquiring an additional 185,000 shares during the period. Ground Swell Capital LLC bought a new stake in Compass Therapeutics in the 2nd quarter valued at $124,000. Vanguard Group Inc. lifted its position in Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after acquiring an additional 71,008 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares during the period. Institutional investors own 68.43% of the company’s stock.
Compass Therapeutics Trading Down 0.5 %
NASDAQ CMPX opened at $1.85 on Tuesday. The firm has a market capitalization of $254.54 million, a P/E ratio of -5.14 and a beta of 0.90. The firm’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $1.39. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $2.34.
Analysts Set New Price Targets
Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, August 12th. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Monday, September 16th.
Read Our Latest Report on Compass Therapeutics
Compass Therapeutics Company Profile
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Read More
- Five stocks we like better than Compass Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Best Aerospace Stocks Investing
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Best Stocks Under $10.00
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report).
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.